Showing 29,181 - 29,200 results of 29,425 for search 'aiming optimization', query time: 0.25s Refine Results
  1. 29181

    THE TERM COMBINATION AND THE METAPHOR IN THE OFFICIAL BUSINESS DOCUMENT: COGNITIVE ASPECT by Yuliya I. Demyanchuk.

    Published 2023-05-01
    “…The first of the two linguistic analyses was aimed at giving the global perspective on the most frequent term combinations and comparing them with the most commonly used word combinations in the parallel corpus of the official texts to identify the coefficient of their informational value. …”
    Get full text
    Article
  2. 29182

    Interpretive structural modeling of the implementation of the comprehensive scientific map of Iran by Bahram Akbari, Abouzar Alidadi Talkhestani, Mohammad Reza Navab Esfahani, Meysam Alipour

    Published 2024-09-01
    “…Purpose: The present study aims to present an "interpretive structural modeling of the implementation of the country's comprehensive scientific map." …”
    Get full text
    Article
  3. 29183

    Role of Genetic Testing and Complex Endoscopic Examination in Differential Diagnosis of Hereditary Polyposes in Pediatric and Adolescent Patients: 10 Years Clinical Experience by Tatiana S. Belysheva, Tatiana V. Nasedkina, Timur T. Valiev, Elena V. Sharapova, Vera V. Semenova, Valentina M. Kozlova, Svetlana N. Mikhaylova, Irina S. Kletskaya, Alexey V. Butuzov, Yana V. Vishnevskaja, Valeria V. Lozovaya, Olga A. Gusarova, Armen O. Tumanyan, Olga A. Malichova, Svetlana R. Varfolomeeva

    Published 2023-08-01
    “…The case follow-up tactics in hereditary polyposes have significant differences, and differential diagnosis can be complicated due to the phenotype variability and the clinical manifestations similarity. Objective. The aim of the study is to determine the role of molecular genetic testing and endoscopic examination in the diagnosis and management of children with HPS. …”
    Get full text
    Article
  4. 29184

    Exploring the utility of ultrasound to assess disuse atrophy in different muscles of the lower leg by Edward J. Hardy, Joseph J. Bass, Thomas B. Inns, Mathew Piasecki, Jessica Piasecki, Craig Sale, Robert H. Morris, Jonathan N. Lund, Ken Smith, Daniel J. Wilkinson, Philip J. Atherton, Bethan E. Phillips

    Published 2024-12-01
    “…., TA for falls prevention in older adults), future research should aim to optimize accessible methods to determine muscle losses across the body.…”
    Get full text
    Article
  5. 29185

    Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study by Jae-Bum Jun, Hye-Soon Lee, Sang-Hyon Kim, Seung-Geun Lee, Doo-Ho Lim, Jinhyun Kim, Yong-Beom Park, Mie Jin Lim, Seung-Jae Hong, Hyo-Jin Choi, Shin-Seok Lee, Hyun Ah Kim, Jiwon Hwang, Chang-Hee Suh, Seungwoo Han, Jung-Yoon Choe, Wan-Hee Yoo, Jung Soo Song

    Published 2025-05-01
    “…Epaminurad is a novel selective human urate transporter 1 (hURAT1) inhibitor that has been shown to reduce serum urate (sUA) levels in healthy volunteers and patients with gout. The aims of the current study were to evaluate the urate-lowering efficacy and safety of epaminurad compared with placebo in patients with gout, and to determine the optimal dose. …”
    Get full text
    Article
  6. 29186

    Chronic Myeloid Leukemia Patient Registry in the Russian Federation: From Observational Studies to the Efficacy Evaluation in Clinical Practice by AG Turkina, NV Novitskaya, AK Golenkov, VA Shuvaev, LI Napso, V Krylova, AM Savrilova, GSh Safuanova, AV Korobkin, TYu Klitochenko, EV Burnasheva, EV Vasil’ev, OM Senderova, EYu Fedorova, LM Yalunina, EK Nekhai, GB Kuchma, AS Lyamkina, NG Shchedrova

    Published 2017-07-01
    “…No CS or MGS data were presented for 34 %, 35 % and 63 % of patients during this period. Optimal molecular response and major molecular response (MMR) for TKI therapy were observed in 23 % and 58 % of patients treated < 12 months and > 12 months, respectively. …”
    Get full text
    Article
  7. 29187
  8. 29188

    Efficacy and safety of online adaptive magnetic resonance-guided fractionated stereotactic radiotherapy for brain metastases in non-small cell lung cancer (GASTO-1075): a single-ar... by Shiyang Zheng, Shouliang Ding, Biaoshui Liu, Yixin Xiong, Rui Zhou, Pengxin Zhang, Fangjie Liu, Yimei Liu, Meining Chen, Yu Situ, Mengru Wang, Xiaoyan Huang, Shaohan Yin, Wenfeng Fang, Yonggao Mou, Bo Qiu, Daquan Wang, Hui Liu

    Published 2025-04-01
    “…Summary: Background: Brain metastases (BMs) in non-small cell lung cancer (NSCLC) are associated with poor prognosis and quality of life (QoL). This study aimed to evaluate the efficacy and safety of online adaptive MR-guided fractionated stereotactic radiotherapy (FSRT) using a 1.5 T MR-Linac in this subgroup of patients. …”
    Get full text
    Article
  9. 29189

    Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors by Yun Zhang, Bhumsuk Keam, Jayesh Desai, Ben Markman, Shahneen Sandhu, Michael Millward, Yoon-Koo Kang, Chia-Chi Lin, Yee Chao, Sanjeev Deva, Jong Seok Lee, Chia-Jui Yen, Michael Jameson, Ming-Mo Hou, Chang-Hsien Lu, Kun-Ming Rau, Kyung-Hun Lee, Lisa Horvath, Michael Friedlander, Andrew Hill, Paula Barlow, Chi-Yuan Wu, Liang Liang, John Wu, Virginia Paton

    Published 2020-05-01
    “…Tislelizumab, an investigational monoclonal antibody with high affinity and binding specificity for PD-1, was engineered to minimize binding to FcγR on macrophages to limit antibody-dependent phagocytosis, a potential mechanism of resistance to anti-PD-1 therapy. The aim of this phase IA/IB study was to investigate the safety/tolerability, antitumor effects and optimal dose and schedule of tislelizumab in patients with advanced solid tumors.Methods Patients (aged ≥18 years) enrolled in phase IA received intravenous tislelizumab 0.5, 2, 5 or 10 mg/kg every 2 weeks; 2 or 5 mg/kg administered every 2 weeks or every 3 weeks; or 200 mg every 3 weeks; patients in phase IB received 5 mg/kg every 3 weeks. …”
    Get full text
    Article
  10. 29190

    Prevalence and prediction of hepatocellular carcinoma in alcohol-associated liver disease: a retrospective study of 136 571 patients with chronic liver diseases by Li Gao, Lin Han, Qiaoling Wang, Yinying Lu, Binxia Chang, Hui Tian, Ang Huang, Xingran Zhai, Xueyuan Jin, Qingsheng Liang, Baosen Li, Huan Xie, Dong Ji, Zhengsheng Zou

    Published 2024-02-01
    “…The nomogram model established here with its high accuracy and easy-to-use features achieved an optimal prediction of HCC development in patients with ALD, which can help clinicians to develop an individualised and precise treatment strategy.…”
    Get full text
    Article
  11. 29191

    Natural compounds targeting inflammation and oxidative stress in intestinal ischemia-reperfusion injury: a comprehensive review by Balaji Venkataraman, Aya A. Touny, Shamanth Neralagundi Harihar gowdru, Bhoomendra A. Bhongade, Rajesh B. Patil, Shreesh Ojha, Mauro Pessia, Sandeep B. Subramanya

    Published 2025-08-01
    “…The objective is to provide a comprehensive analysis of the mechanistic pathways targeted by these natural compounds and to highlight areas requiring further research for optimizing clinical applications. Method: The review systematically compiled data from clinical trials, systematic reviews, meta-analyses, and recent peer-reviewed studies published over the past decade. …”
    Get full text
    Article
  12. 29192

    Dosimetric investigation of couch rotation angles in non-coplanar VMAT plans for lung cancer SBRT by Weiqiang Ye, Housheng Wang, Zhenzhen Wei, Wei Zhang, Chaojun Yu, Dawei Zhang, Shida Su, Wen Qin, Kai Hu, Kai Hu, Kai Hu, Kai Hu, Bo Li

    Published 2024-12-01
    “…Our study offers theoretical support for the preferential use of ncVMAT plans in lung cancer SBRT and provides empirical evidence to guide the selection of optimal couch rotation angles.…”
    Get full text
    Article
  13. 29193

    Evaluation of Immunogenicity of <i>Mycobacterium tuberculosis ag85ab</i> DNA Vaccine Delivered by Pulmonary Administration by Haimei Zhao, Zhen Zhang, Yong Xue, Nan Wang, Yinping Liu, Xihui Ma, Lan Wang, Xiaoou Wang, Danyang Zhang, Junxian Zhang, Xueqiong Wu, Yan Liang

    Published 2025-04-01
    “…<b>Background:</b> Tuberculosis (TB) is a respiratory infectious disease, and the current TB vaccine has low local lung protection. We aim to optimize immune pathways to improve the immunogenicity of vaccines. …”
    Get full text
    Article
  14. 29194

    Comparative efficacy of rTMS on different targets in Alzheimer’s disease: a systematic review and meta-analysis by Yushu Zhang, Yushu Zhang, Ke Dong, Ke Dong, Jiajia Yang, Jiajia Yang, Qifan Guo, Qifan Guo, Yan Zhao, Yan Zhao, Xiaoxia Zhu, Xiaoxia Zhu, Dongxu Liu, Dongxu Liu, Peng Liu, Peng Liu

    Published 2025-04-01
    “…These findings contribute to the development of optimized, personalized rTMS protocols for AD treatment.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/recorddashboard, CRD42023434084.…”
    Get full text
    Article
  15. 29195

    Does pregabalin offer potential as a first-line therapy for generalized anxiety disorder? A meta-analysis of efficacy, safety, and cost-effectiveness by Narcis Cardoner, Narcis Cardoner, Narcis Cardoner, Narcis Cardoner, Luis Gutiérrez-Rojas, Luis Gutiérrez-Rojas, Pilar Saiz, Pilar Saiz, Pilar Saiz, Pilar Saiz, Pilar Saiz, Guillermo Lahera, Guillermo Lahera, Guillermo Lahera, Guillermo Lahera, Miguel Ángel Álvarez-Mon, Miguel Ángel Álvarez-Mon, Miguel Ángel Álvarez-Mon, Miguel Ángel Álvarez-Mon, Pino Alonso Ortega, Pino Alonso Ortega, Pino Alonso Ortega, Pino Alonso Ortega, María Pérez-Páramo

    Published 2025-02-01
    “…Pregabalin has shown promise in reducing anxiety symptoms; however, further research is needed to evaluate its efficacy and compare it with other treatment options. This study aimed to assess the efficacy, safety, and optimal pregabalin dosage for the treatment of GAD.MethodsThis meta-analysis followed PRISMA guidelines. …”
    Get full text
    Article
  16. 29196

    Imaging features of desmoplakin arrhythmogenic cardiomyopathy: A comparative cardiovascular magnetic resonance study by Mikael Laredo, Etienne Charpentier, Shannon Soulez, Vincent Nguyen, Annamaria Martino, Leonardo Calò, Flavie Ader, Alexis Hermida, Véronique Fressart, Philippe Charron, Nadjia Kachenoura, Estelle Gandjbakhch, Alban Redheuil

    Published 2025-01-01
    “…Whether DSP-ACM is associated with specific imaging features remains elusive. This study aims to provide a comprehensive description of cardiovascular magnetic resonance (CMR) findings in patients with DSP-ACM and to compare them to RV-dominant ACM with LV involvement (LV+ right-dominant-ACM). …”
    Get full text
    Article
  17. 29197

    Effective cellular and neutralizing immunity against SARS-CoV-2 after mRNA booster vaccination is associated with pDC and B cell activation by Dorit Fabricius, Carolin Ludwig, Carolin Ludwig, Matthias Proffen, Matthias Proffen, Janina Hägele, Janina Hägele, Judith Scholz, Judith Scholz, Christiane Vieweg, Christiane Vieweg, Immanuel Rode, Immanuel Rode, Simone Hoffmann, Simone Hoffmann, Sixten Körper, Sixten Körper, Hubert Schrezenmeier, Hubert Schrezenmeier, Bernd Jahrsdörfer, Bernd Jahrsdörfer

    Published 2025-05-01
    “…The study underscores the importance of integrated humoral and cellular immune responses, suggesting potential for optimized booster strategies and pDC-targeted vaccine designs to enhance long-term protection against SARS-CoV-2 and emerging variants.…”
    Get full text
    Article
  18. 29198

    Renal resistive index as an early predictor and discriminator of acute kidney injury in critically ill patients; A prospective observational cohort study. by Jelle L G Haitsma Mulier, Sander Rozemeijer, Jantine G Röttgering, Angelique M E Spoelstra-de Man, Paul W G Elbers, Pieter Roel Tuinman, Monique C de Waard, Heleen M Oudemans-van Straaten

    Published 2018-01-01
    “…On univariate analysis, RRI significantly predicted AKI 2-3: OR 1.012 (1.006-1.019); Area Under the Curve (AUC) of RRI for AKI 2-3 was 0.72 (0.61-0.83), optimal cut-off 0.74, sensitivity 53% and specificity 87%. …”
    Get full text
    Article
  19. 29199
  20. 29200

    Changes in serum concentration of perioperative inflammatory cytokines following the timing of surgery among mild–moderate traumatic brain injury patients and factors associated by Hervé Monka Lekuya, Hervé Monka Lekuya, Stephen Cose, Marjorie Nakibuule, Gift Ahimbisibwe, Anthony Fuller, Larrey Kasereka Kamabu, Emmanuel Biryabarema, Geoffrey Olweny, David Patrick Kateete, Anthony Kirabira, Fredrick Makumbi, Jelle Vandersteene, Edward Baert, Moses Galukande, Jean-Pierre Okito Kalala

    Published 2024-12-01
    “…BackgroundThe safe timing window for surgery during the acute phase of inflammation due to traumatic brain injury (TBI) has not been studied extensively. We aimed to elucidate the relationship between the timing of surgery and changes in perioperative serum levels of inflammatory cytokines and factors associated to optimize TBI management in low-middle-income countries.MethodsA prospective cohort study was conducted among TBI Patients with depressed skull fractures with a GCS &gt; 8 operated at different timing from injury and followed up peri-operatively. …”
    Get full text
    Article